Eric van der Veer, Ph.D.Chief Scientific Officer at Hybridize Therapeutics
Eric studied Chemistry at the University of Amsterdam (M.Sc), and pursued a Ph.D. degree in Biochemistry at the University of Western Ontario (Canada). He returned to the Netherlands (LUMC) and started his own research group specializing in RNA biology of healthy and diseased cells, yielding publications in Nature Communications, European Heart Journal and Circulation Research. For his work, he was awarded the Irvine H. Page Award by the American Heart Association. In 2015, he conceived a novel method of targeting polyomaviruses. To further develop this concept and transition the therapy to the clinic, he left the LUMC in 2019 and founded Hybridize Therapeutics.